Company intelligence / Profile preview

MVision AI

Helsinki, Finland

Ownership: Private
Employees: ~72
Development stage: Other

Overview

MVision AI is a Finnish company specializing in AI-powered medical imaging software for radiotherapy treatment planning. Their commercial platforms, Guideline-Based Segmentation Suite (GBS™) and Dose+, are used globally to automate and standardize radiotherapy, particularly for prostate and pelvic lymph node cancers. These solutions support real-world clinical workflows, enhancing accuracy and efficiency for over 190,000 cancer patients annually.

Therapeutic areas: Oncology
Modalities: DeviceSoftware
Industry: Medical Imaging

Beyond the preview

Go deeper on MVision AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVision AI.

Explore the full profile